+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily



Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily



Acta Ophthalmologica Scandinavica 81(3): 242-246



Purpose: To evaluate the efficacy and safety of the timolol maleate/latanoprost fixed combination (TLFC) given once each evening versus brimonidine and timolol solution given twice daily as concomitant therapy in primary open-angle glaucoma or ocular hypertension patients. Methods: Qualified subjects were begun on timolol alone twice daily for 1 month and then randomized to either TLFC or brimonidine and timolol concomitant therapy for 6 weeks. Patients were then switched to the other treatment regimen. Intraocular pressures (lOPs) were measured every 2hours between 08:00 and 20:00 hours at baseline and at the end of periods 1 and 2. Results: This study found that in 32 subjects the IOP diurnal curve on timolol alone (20.9 +- 2.8 mmHg) decreased to 17.9 +- 3.2 mmHg when patients were treated with TLFC and to 19.0 +- 2.4 mmHg when patients were treated with brimonidine and timolol (p=0.02). Intraocular pressures at individual time-points were statistically similar between the groups at the 08:00 trough and 2 and 4 hours after dosing. However, beyond 4 hours after dosing, TLFC-treated subjects demonstrated a trend towards lower IOPs at each 2-hour time-point that was not statistically significant after a Bonferroni correction (p ltoreq 0.05). The incidence of both solicited and unsolicited side-effects was similar between groups. Conclusion: This study suggests that TLFC given in the evening reduces the mean daytime diurnal IOP more than brimonidine and timolol given concomitantly twice daily.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010569325

Download citation: RISBibTeXText

PMID: 12780402

DOI: 10.1034/j.1600-0420.2003.00065.x


Related references

Efficacy and Safety of Latanoprost/Timolol Maleate Fixed Combination Verses Timolol Maleate and Brimonidine Given Twice Daily. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 3430, 2002

Efficacy and safety of latanoprost/timolol maleate fixed combination versus brimonidine given twice daily and latanoprost given each evening. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 4364, 2003

The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP. International Ophthalmology 38(4): 1425-1431, 2018

An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. Journal of Glaucoma 17(8): 674-679, 2008

Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy. Eye 18(10): 990-995, 2004

Efficacy and safety of timolol hemihydrate 05% solution once daily versus timolol maleate gel 05% once daily added to latanoprost 0005%. IOVS 40(4): S513, 1999

Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost. European Journal of Ophthalmology 18(4): 556-562, 2008

Timolol maleate 0.5% versus timolol maleate in gel forming solution 0.5% (Timolol GFS) in open angle glaucoma in India. Preliminary safety and efficacy study. Indian Journal of Ophthalmology 50(1): 21-23, 2002

Efficacy and safety of the fixed combination latanoprost/timolol versus the unfixed combination brimonidine/timolol in patients with elevated intraocular pressure a 6 month, masked evaluator study. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 2198, 2003

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy. Clinical Ophthalmology 6: 771-775, 2012

Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Acta Ophthalmologica 86(8): 860-865, 2008

Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye 18(12): 1264-1269, 2004

Efficacy and safety of switching to latanoprost 0.005%-timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months. Clinical Ophthalmology 8: 1275-1279, 2014

Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Documenta Ophthalmologica. Advances in Ophthalmology 103(1): 73-79, 2001

Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. British Journal of Ophthalmology 88(10): 1295-1298, 2004